Therapeutic Potential of Tenecteplase in the Management of Acute Ischemic Stroke

CNS Drugs

Volumn 29, Issue 10, 2015, Pages 811-818

  Logallo, Nicola ^a,b   Kvistad, Christopher E ^a,b   Thomassen, Lars ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; TENECTEPLASE; NEUROPROTECTIVE AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; HEART INFARCTION; HUMAN; MECHANICAL THROMBECTOMY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; ANIMAL; CHEMISTRY; DISEASE MANAGEMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE;

ANIMALS; BRAIN ISCHEMIA; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE MANAGEMENT; HUMANS; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84947040304     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-015-0280-9     Document Type: Article

References (38)

1. Bluhmki E, Chamorro A, Davalos A, Machnig T, Sauce C, Wahlgren N, et al. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009;8(12):1095-102.
2. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581-7.
3. Hennerici MG, Kay R, Bogousslavsky J, Lenzi GL, Verstraete M, Orgogozo JM, et al. Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial. Lancet. 2006;368(9550):1871-8.
4. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36(1):66-73.
5. Albers GW, von Kummer R, Truelsen T, Jensen JK, Ravn GM, Gronning BA, et al. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Neurol. 2015;14(6):575-84.
6. Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet. 2002;41(15):1229-45.
7. Haley EC Jr, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke. 2010;41(4):707-11.
8. Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366(12):1099-107.
9. Huang X, Cheripelli BK, Lloyd SM, Kalladka D, Moreton FC, Siddiqui A, et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol. 2015;14(4):368-76.
10. Huang X, Fulton R, Parsons M, Levi C, Campbell B, Bladin C, Haley E, Thompson JLP, Levin B, Buchsbaum R, Muir KW, Tenecteplase versus Alteplase in acute ischaemic stroke thrombolysis: a meta-analysis of individual patient data from randomised studies. Abstract - oral presentation. 1st ESO conference, Glasgow, April 17-19, 2015
11. Logallo N, Kvistad CE, Nacu A, Naess H, Waje-Andreassen U, Asmuss J, et al. The Norwegian Tenecteplase Stroke Trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke. BMC Neurol. 2014;14:106.
12. Parsons M. Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) trial. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=363714. Accessed 27 May 2015.
13. Davydov L, Cheng JW. Tenecteplase: a review. Clin Ther. 2001;23(7):982-97 (discussion 981).
14. Smalling RW. Molecular biology of plasminogen activators: what are the clinical implications of drug design? Am J Cardiol. 1996;78(12A):2-7.
15. Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci. 1994;91(9):3670-4.
16. Refino CJ, Paoni NF, Keyt BA, Pater CS, Badillo JM, Wurm FM, et al. A variant of t-PA (T103N, KHRR 296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen. Thromb Haemost. 1993;70(2):313-9.
17. Collen D, Stassen JM, Yasuda T, Refino C, Paoni N, Keyt B, et al. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost. 1994;72(1):98-104.
18. Thomas GR, Thibodeaux H, Errett CJ, Badillo JM, Keyt BA, Refino CJ, et al. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke. 1994;25(10):2072-8 (discussion 2078-9).
19. Cannon CP, McCabe CH, Gibson CM, Ghali M, Sequeira RF, McKendall GR, et al. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation. 1997;95(2):351-6.
20. Cannon CP, Gibson CM, McCabe CH, Adgey AA, Schweiger MJ, Sequeira RF, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation. 1998;98(25):2805-14.
21. Van de Werf F, Cannon CP, Luyten A, Houbracken K, McCabe CH, Berioli S, et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. Am Heart J. 1999;137(5):786-91.
22. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, Van De Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354(9180):716-22.
23. Haley EC Jr, Lyden PD, Johnston KC, Hemmen TM, Investigators TNKiS. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke. 2005;36(3):607-12.
24. Molina CA, Ribo M, Rubiera M, Santamarina E, Delgado-Mederos R, Maisterra O, et al. TNK induces faster MCA recanalization and leads to better short- and long-term clinical outcome than native tPA. The TNK-TPA Reperfusion Stroke Study [abstract]. Stroke. 2008;39(2):563.
25. Parsons MW, Miteff F, Bateman GA, Spratt N, Loiselle A, Attia J, et al. Acute ischemic stroke Imaging-guided tenecteplase treatment in an extended time window. Neurology. 2009;72(10):915-21.
26. Coutts SB, Dubuc V, Mandzia J, Kenney C, Demchuk AM, Smith EE, et al. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion. Stroke. 2015;46(3):769-74.
27. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372(1):11-20.
28. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372(11):1019-30.
29. Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372(11):1009-18.
30. Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015;372(24):2285-95.
31. Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372(24):2296-306.
32. Logallo N, Kvistad CE, Naess H, Waje-Andreassen U, Thomassen L. Mild stroke: safety and outcome in patients receiving thrombolysis. Acta Neurol Scand Suppl. 2014;198:37-40.
33. Laurencin C, Philippeau F, Blanc-Lasserre K, Vallet AE, Cakmak S, Mechtouff L, et al. Thrombolysis for acute minor stroke: outcome and barriers to management. Results from the RESUVAL Stroke Network. Cerebrovasc Dis. 2015;40(1-2):3-9.
34. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768-74.
35. Mikulik R, Kadlecova P, Czlonkowska A, Kobayashi A, Brozman M, Svigelj V, et al. Factors influencing in-hospital delay in treatment with intravenous thrombolysis. Stroke. 2012;43(6):1578-83.
36. Weber JE, Ebinger M, Rozanski M, Waldschmidt C, Wendt M, Winter B, et al. Prehospital thrombolysis in acute stroke: results of the PHANTOM-S pilot study. Neurology. 2013;80(2):163-8.
37. Tsikouris JP, Tsikouris AP. A review of available fibrin-specific thrombolytic agents used in acute myocardial infarction. Pharmacotherapy. 2001;21(2):207-17.
38. Modi NB, Fox NL, Clow FW, Tanswell P, Cannon CP, Van de Werf F, et al. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. J Clin Pharmacol. 2000;40(5):508-15.